{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:01:51Z","timestamp":1792710111763,"version":"4.5.0"},"reference-count":31,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,12]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Richter transformation (RT) to diffuse large B-cell lymphoma is an aggressive lymphoma that arises from underlying chronic lymphocytic leukemia or small lymphocytic lymphoma. RT is often chemorefractory, resulting in poor clinical outcomes with standard chemoimmunotherapy. Mosunetuzumab, a bispecific CD20\/CD3 T-cell\u2013engaging antibody, was investigated in a cohort of 20 patients with relapsed\/refractory RT. Cytokine release syndrome occurred in 65% of patients, almost exclusively grade 1 (20%) or grade 2 (40%), and occurring during the first treatment cycle. Other adverse events included infections, neutropenia, thrombocytopenia, tumor flare, and low-grade neurotoxicity, with no adverse events leading to treatment discontinuation. Mosunetuzumab resulted in an overall response rate of 40% and a complete response (CR) rate of 20%. CRs were durable, with 2 patients experiencing CR for &amp;gt;20 months without further therapy, and 2 were able to proceed to allogeneic stem cell transplant while in CR, with no subsequent relapse. Median progression-free survival and overall survival were 3.4 and 10.2 months, respectively. Given the favorable toxicity profile of mosunetuzumab and rapid and durable CRs observed in this cohort, further investigation of mosunetuzumab for the treatment of RT, as monotherapy and in combination with other novel agents or chemotherapy, is warranted. This trial was registered at www.ClinicalTrials.gov as NCT02500407.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025017914","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T21:40:37Z","timestamp":1770327637000},"page":"3011-3019","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["Mosunetuzumab monotherapy is active and tolerable in patients with relapsed\/refractory Richter transformation"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0549-5877","authenticated-orcid":false,"given":"Katharine L.","family":"Lewis","sequence":"first","affiliation":[{"name":"1Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, Australia"},{"name":"2Linear Clinical Research, Nedlands, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7638-1589","authenticated-orcid":false,"given":"Sarit E.","family":"Assouline","sequence":"additional","affiliation":[{"name":"3Division of Hematology, Jewish General Hospital, Montreal, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2728-6788","authenticated-orcid":false,"given":"Ross","family":"Baker","sequence":"additional","affiliation":[{"name":"4Perth Blood Institute, Perth, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8470-394X","authenticated-orcid":false,"given":"Nancy L.","family":"Bartlett","sequence":"additional","affiliation":[{"name":"5Division of Oncology, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2752-5814","authenticated-orcid":false,"given":"Dima","family":"El-Sharkawi","sequence":"additional","affiliation":[{"name":"6Department of Haematology, The Royal Marsden Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratyush","family":"Giri","sequence":"additional","affiliation":[{"name":"7Department of Haematology, Royal Adelaide Hospital, Central Adelaide Local Health Network, Adelaide, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9289-1335","authenticated-orcid":false,"given":"Matthew","family":"Ku","sequence":"additional","affiliation":[{"name":"8Department of Haematology, St Vincent\u2019s Hospital and The University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4581-3721","authenticated-orcid":false,"given":"Matthew","family":"Matasar","sequence":"additional","affiliation":[{"name":"9Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3376-8978","authenticated-orcid":false,"given":"Stephen","family":"Schuster","sequence":"additional","affiliation":[{"name":"10Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7898-2786","authenticated-orcid":false,"given":"John","family":"Radford","sequence":"additional","affiliation":[{"name":"11Department of Medical Oncology, University of Manchester and The Christie NHS Foundation Trust, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Wei","sequence":"additional","affiliation":[{"name":"12Genentech Inc, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shen","family":"Yin","sequence":"additional","affiliation":[{"name":"12Genentech Inc, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Kwan","sequence":"additional","affiliation":[{"name":"12Genentech Inc, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"To","sequence":"additional","affiliation":[{"name":"12Genentech Inc, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibha","family":"Raghavan","sequence":"additional","affiliation":[{"name":"12Genentech Inc, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1464-5494","authenticated-orcid":false,"given":"Lihua E.","family":"Budde","sequence":"additional","affiliation":[{"name":"13Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7988-1565","authenticated-orcid":false,"given":"Chan Y.","family":"Cheah","sequence":"additional","affiliation":[{"name":"1Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, Australia"},{"name":"2Linear Clinical Research, Nedlands, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"issue":"6","key":"2026051211563555200_bib1","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/bjh.12458","article-title":"Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients","volume":"162","author":"Parikh","year":"2013","journal-title":"Br J Haematol"},{"issue":"10","key":"2026051211563555200_bib2","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1038\/leu.2016.113","article-title":"Effect of first-line treatment on second primary malignancies and Richter's transformation in patients with CLL","volume":"30","author":"Maurer","year":"2016","journal-title":"Leukemia"},{"issue":"10","key":"2026051211563555200_bib3","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1007\/s00277-021-04603-y","article-title":"Outcomes of Richter's transformation of chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): an analysis of the SEER database","volume":"100","author":"Elnair","year":"2021","journal-title":"Ann Hematol"},{"issue":"3","key":"2026051211563555200_bib4","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3324\/haematol.2019.224121","article-title":"Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center","volume":"105","author":"Wang","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"2026051211563555200_bib5","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41375-020-0797-x","article-title":"Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials","volume":"35","author":"Al-Sawaf","year":"2021","journal-title":"Leukemia"},{"issue":"4","key":"2026051211563555200_bib6","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/ajh.23939","article-title":"Hodgkin transformation of chronic lymphocytic leukemia: incidence, outcomes, and comparison to de novo Hodgkin lymphoma","volume":"90","author":"Parikh","year":"2015","journal-title":"Am J Hematol"},{"issue":"12","key":"2026051211563555200_bib7","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1182\/blood-2010-09-302174","article-title":"The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation","volume":"117","author":"Rossi","year":"2011","journal-title":"Blood"},{"issue":"6","key":"2026051211563555200_bib8","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/bjh.16748","article-title":"Clinical outcome and prognostic factors of patients with Richter syndrome: real-world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC)","volume":"190","author":"Abrisqueta","year":"2020","journal-title":"Br J Haematol"},{"issue":"8","key":"2026051211563555200_bib9","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1038\/s41375-025-02666-8","article-title":"Richter transformation in diffuse large B-cell lymphoma in patients with chronic lymphocytic leukemia receiving ibrutinib: risk factors and outcomes","volume":"39","author":"Pepe","year":"2025","journal-title":"Leukemia"},{"issue":"suppl 1","key":"2026051211563555200_bib10","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1182\/blood-2021-147146","article-title":"Real world data on the outcomes of Richter's transformation of chronic lymphocytic leukemia and small lymphocytic lymphoma in the Australian population: an Australasian Lymphoma Alliance Study","volume":"138","author":"Walker","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2026051211563555200_bib11","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41408-025-01236-6","article-title":"Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL","volume":"15","author":"Kittai","year":"2025","journal-title":"Blood Cancer J"},{"issue":"suppl 1","key":"2026051211563555200_bib12","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1182\/blood-2022-155950","article-title":"Predictors of adverse clinical outcome in diffuse large B-cell lymphoma Richter transformation of CLL\/SLL: a Consortium of Richter Transformation Investigators (CORTI) multicenter study across 8 US, UK, and Australian academic centers","volume":"140","author":"Symes","year":"2022","journal-title":"Blood"},{"issue":"2","key":"2026051211563555200_bib13","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/bjh.15035","article-title":"A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor","volume":"180","author":"Rogers","year":"2018","journal-title":"Br J Haematol"},{"issue":"7","key":"2026051211563555200_bib14","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1002\/cncr.11238","article-title":"Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia","volume":"97","author":"Tsimberidou","year":"2003","journal-title":"Cancer"},{"issue":"2","key":"2026051211563555200_bib15","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1200\/JCO.2007.11.8513","article-title":"Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia","volume":"26","author":"Tsimberidou","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"2026051211563555200_bib16","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3109\/10428190109064589","article-title":"Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter's syndrome","volume":"42","author":"Dabaja","year":"2001","journal-title":"Leuk Lymphoma"},{"issue":"suppl 1","key":"2026051211563555200_bib17","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1182\/blood-2019-123933","article-title":"Pharmacodynamic effects and immune correlates of response to the CD20\/CD3 bispecific antibody mosunetuzumab in relapsed or refractory non-Hodgkin lymphoma","volume":"134","author":"Hernandez","year":"2019","journal-title":"Blood"},{"issue":"287","key":"2026051211563555200_bib18","doi-asserted-by":"crossref","first-page":"287ra70","DOI":"10.1126\/scitranslmed.aaa4802","article-title":"Anti-CD20\/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies","volume":"7","author":"Sun","year":"2015","journal-title":"Sci Transl Med"},{"issue":"5","key":"2026051211563555200_bib19","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.21.00931","article-title":"Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study","volume":"40","author":"Budde","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026051211563555200_bib20","volume-title":"Lunsumio: FDA prescribing information","year":"2022"},{"key":"2026051211563555200_bib21","volume-title":"Lunsumio: summary of product characteristics","year":"2022"},{"issue":"4","key":"2026051211563555200_bib22","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"5","key":"2026051211563555200_bib23","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"17","key":"2026051211563555200_bib24","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1182\/bloodadvances.2022009260","article-title":"Mosunetuzumab monotherapy is active and tolerable in patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"7","author":"Bartlett","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"2026051211563555200_bib25","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3390\/cancers17010095","article-title":"Updates in the management of Richter transformation","volume":"17","author":"Rippel","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"19","key":"2026051211563555200_bib26","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1200\/JCO.23.02329","article-title":"Durable responses with mosunetuzumab in relapsed\/refractory indolent and aggressive B-cell non-Hodgkin lymphomas: extended follow-up of a phase I\/II study","volume":"42","author":"Budde","year":"2024","journal-title":"J Clin Oncol"},{"issue":"7","key":"2026051211563555200_bib27","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1182\/blood.2024025454","article-title":"Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after \u22652 prior therapies","volume":"145","author":"Sehn","year":"2025","journal-title":"Blood"},{"issue":"suppl 1","key":"2026051211563555200_bib28","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1182\/blood-2022-158298","article-title":"Subcutaneous epcoritamab in patients with Richter's syndrome: early results from phase 1b\/2 trial (EPCORE CLL-1)","volume":"140","author":"Kater","year":"2022","journal-title":"Blood"},{"issue":"S2","key":"2026051211563555200_bib29","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/hon.3163_28","article-title":"Glofitamab monotherapy induces durable complete remissions and has a manageable safety profile in patients with Richter\u2019s transformation","volume":"41","author":"Carlo-Stella","year":"2023","journal-title":"Hematological Oncol"},{"issue":"14","key":"2026051211563555200_bib30","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1182\/bloodadvances.2023011089","article-title":"Predictive model for the risk of cytokine release syndrome with glofitamab treatment for diffuse large B-cell lymphoma","volume":"8","author":"Gritti","year":"2024","journal-title":"Blood Adv"},{"issue":"18","key":"2026051211563555200_bib31","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J Clin Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/9\/3011\/2515921\/blooda_adv-2025-017914-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/9\/3011\/2515921\/blooda_adv-2025-017914-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:56:49Z","timestamp":1778601409000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/9\/3011\/566437\/Mosunetuzumab-monotherapy-is-active-and-tolerable"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,5,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025017914","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,12]]},"published":{"date-parts":[[2026,4,30]]}}}